Table 3.
Characteristics | Disease progression | Overall mortality | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
Univariate | Multivariate | Univariate | Multivariate | |||||||||
Hazard ratio | 95% CI | p value | Hazard ratio | 95% CI | p value | Hazard ratio | 95% CI | p value | Hazard ratio | 95% CI | p value | |
Gender (male vs. female) | 0.529 | 0.217–1.291 | 0.162 | 0.529 | 0.224–1.251 | 0.147 | ||||||
Age ≥ 60 vs. < 60 | 3.856 | 1.372–10.836 | 0.010 | 3.856 | 1.372–10.836 | 0.010 | 2.631 | 1.017–6.802 | 0.046 | |||
pT Stage (pT3,4 vs. pT1,2) | 1.791 | 0.746–4.301 | 0.192 | 2.498 | 0.982–6.356 | 0.055 | ||||||
Grade (3,4 vs. 1,2) | 1.737 | 0.763–3.956 | 0.188 | 2.851 | 1.174–6.923 | 0.021 | ||||||
Venous invasion (yes vs. no) | 1.695 | 0.731–3.929 | 0.219 | 2.401 | 0.988–5.838 | 0.053 | ||||||
CD8+ T-cell heterogeneity | 2.228 | 0.899–5.523 | 0.084 | 2.881 | 1.217–6.819 | 0.016 | 3.436 | 1.370–8.619 | 0.009 | |||
(CD8highCD39highPD-1high vs. CD8highCD39highPD-1low) |